The TRIPS study is testing a drug called anakinra to help children with sepsis-induced multiple organ dysfunction syndrome, or MODS. MODS is when different parts of the body start having trouble working because of a severe infection. The study is double-blind, meaning neither the doctors nor the patients know who gets the actual medicine and who gets a fake one called a placebo. The study aims to see if anakinra can reduce the inflammation (swelling) that happens when children have serious infections.
Eligible children are those who are sick with MODS and meet certain criteria based on their immune system's response and levels of inflammation markers like ferritin and C-reactive protein (CRP). Kids who join the study will get anakinra through an IV (a needle in their vein) or a placebo for 7 days. The dose depends on their weight.
- Length: 7 days of treatment.
- Eligibility: Children up to 18 years old in intensive care with at least 2 organ dysfunctions.
- Risks: Possible side effects from anakinra, but closely monitored by medical staff.